UK biotech is booming, with the number of R&D companies increasing 65% since 2016 amid soaring annual investment of more than £2 billion, according to a new report.
Drug development can be quite a risky business at the best of times, but particularly in the biotech sector where companies may only have a few assets to their name.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.